Predictors of the use of complementary and alternative medicine (CAM) by women at high risk for breast cancer

KM Field; MA Jenkins; ML Friedlander; JM McKinley; MA Price; P Weideman; LA Keogh; SA McLachlan; GJ Lindeman; JL Hopper; PN Butow; KA Phillips

Journal article

Predictors of the use of complementary and alternative medicine (CAM) by women at high risk for breast cancer

KM Field, MA Jenkins, ML Friedlander, JM McKinley, MA Price, P Weideman, LA Keogh, SA McLachlan, GJ Lindeman, JL Hopper, PN Butow, KA Phillips

European Journal of Cancer | ELSEVIER SCI LTD | Published : 2009

DOI: 10.1016/j.ejca.2008.09.023

Abstract

Background: Few data exist regarding the use of complementary and alternative medicine (CAM) by unaffected women at high risk of breast cancer. Methods: Self-reported CAM use by women from multiple-case breast cancer families was obtained by questionnaire. Factors associated with CAM use were assessed using multiple logistic regression. Results: Of 892 women, 55% (n = 489) used CAM, 6% (n = 53) specifically to prevent cancer. CAM use was independently associated with tertiary education level (OR 2.56, 95% CI 1.83-3.58, p < 0.001), greater physical activity (OR 1.05 per hour of physical activity/week, 95% CI 1.00-1.10, p = 0.049), greater anxiety (OR 1.92, 95% CI 1.16-3.16, p = 0.01), not cur..

View full abstract

University of Melbourne Researchers

Kathryn Field Author

Mark Jenkins Author

Louise Keogh Author

Sue-Anne McLachlan Author

Related Projects (2)

RISK FACTORS, SCREENING, PROPHYLAXIS AND OUTCOMES IN INDIVIDUALS FROM BREAST CANCER FAMILIES: KCONFAB FOLLOW-UP STUDY

Having a strong family history of breast cancer is one of the most important risk factors for the disease. Two major genes, BRCA1 and BRCA2,..

How can the risk of breast cancer be reduced in those with a strong family history of the disease?

Having a strong family history for breast cancer is one of the most important risk factors for the disease. Two major genes, BRCA1 and BRCA2..

Grants

Awarded by National Health and Medical Research Council

Funding Acknowledgements

This study was funded by the National Health and Medical Research Council (NHMRC) of Australia (#145684, 288704, 454508, 153824, 301930, 457316). KA Phillips is supported by the Cancer Council Victoria John Colebatch Clinical Research Fellowship. John Hopper is an Australia Fellow of the NHMRC and Victorian Breast Cancer Research Consortium Group Leader. kConFab is supported by grants from the National Breast Cancer Foundation, the National Health and Medical Research Council of Australia and by the Queensland Cancer Fund, the Cancer Councils of New South Wales, Victoria, Tasmania and South Australia, the Cancer Foundation of Western Australia, Perpetual Philanthropic Foundations of New South Wales and the Breast Cancer Research Association.